William Herring

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF MEDICAL ECONOMICS. 2024;27(1):109-125
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; Mccombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
Article: PHARMACOECONOMICS (AUCKLAND). 2024;42(6):693-714
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
Herring WL; Gallagher ME; Shah N; Morse K; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
Article: NEUROLOGY AND THERAPY. 2024;13(1):53-67
Evaluating Elements of the Care Partner Experience in Individuals Who Care for People with Alzheimer's Disease Across the Severity Spectrum
Callahan LF; Samsell B; Dibenedetti D; Frangiosa T; Slota C; Biggar V; Paulsen R; Lappin D; Herring WL; Romano C
Article: VACCINES. 2024;12(1):74
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States
Paret K; Beyhaghi H; Herring WL; Mauskopf J; Shane LG; Rousculp MD
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(5):1800-1820
Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge
Handels RLH; Green C; Gustavsson A; Herring WL; Winblad B; Wimo A; Skoldunger A; Karlsson A; Anderson R; Belger M; Bruck C; Espinosa R; Hlavka JP; Jutkowitz E; Lin P-J; Mendez ML; Mar J; Shewmaker P; Spackman E; Tafazzoli A; Tysinger B; Jonsson L
Article: VALUE IN HEALTH. 2023;26(4):508-518
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study
Li X; Hodgson D; Flaig J; Kieffer A; Herring WL; Beyhaghi H; Willem L; Jit M; Bilcke J; Beutels P
Article: JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH. 2022;11(18):1349-1363
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes
Herring WL; Gould IG; Wittrup-Jensen V; Ertle J; Kuti E; Wolowacz S
Article: EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH. 2022;22(4):529-541
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States
Herring W; Ciarametaro M; Mauskopf J; Wamble D; Sils B; Dubois R
Article: PHARMACOECONOMICS (AUCKLAND). 2022;40(3):323-339
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H
Article: VACCINE. 2022;40(3):483-493
Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States
Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
Article: NEUROLOGY AND THERAPY. 2021;10(2):919-940
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Article: MAYO CLINIC PROCEEDINGS: INNOVATIONS, QUALITY & OUTCOMES. 2021;5(3):596-604
Estimated Public Health Impact of the Recombinant Zoster Vaccine.
Patterson BJ; Buck PO; Curran D; Van Oorschot D; Carrico J; Herring WL; Zhang Y; Stoddard JJ
Article: JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY. 2020;26(12):1567-1575
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng H-F
Article: PHARMACOECONOMICS (AUCKLAND). 2016;34(1):77-90
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
Herring W; Pearson I; Purser M; Nakhaipour HR; Haiderali A; Wolowacz S; Jayasundara K
Article: OR SPECTRUM. 2012;34(2):429-459
The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics
Herring WL; Herrmann JW
Article: PRODUCTION AND OPERATIONS MANAGEMENT. 2011;20(3):431-441
Reducing Boarding in a Post-Anesthesia Care Unit
Price C; Golden B; Harrington M; Konewko R; Wasil E; Herring W

Alla övriga publikationer

Review: JOURNAL OF INTERNAL MEDICINE. 2024;295(3):281-291
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
Wahlberg K; Winblad B; Cole A; Herring WL; Ramsberg J; Torontali I; Visser P-J; Wimo A; Wollaert L; Jonsson L

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI